ProQR Therapeutics N.V. financial data

Symbol
PRQR on Nasdaq
Location
Leiden, Netherlands
Fiscal year end
31 December
Latest financial report
6-K - Q3 2024 - 07 Nov 2024

Income Statement

Label TTM Value / Value Unit Change %
Research And Development Expense €33,478,000 EUR 19%
General And Administrative Expense €14,498,000 EUR 0.28%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets €106,851,000 EUR -25%
Liabilities €81,869,000 EUR -14%